Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs MGTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: CAPR 1 – 5 MGTX Matrix Metrics: CAPR 0 – 10 MGTX

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas MGTX carries 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin).

  • Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs MGTX
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.85
-3.59% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.65β · 68% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 48.0 Fund 57.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 41
RSI-14: 41.5 · SMA20: $9.39 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (CAPR 1 – 5 MGTX)

Columns: Metric · CAPR · MGTX
1. Valuation Multiples MGTX
Forward P/E 78.7x 64.1x
Trailing P/E 78.7x 10.1x
PEG Ratio 0.38x N/M
EV / Revenue 57.8x 2.0x
2. Growth & Scale MGTX
Revenue Growth (YoY) -7.9% +8608.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $398M
Market Cap $595.4M $844.2M
3. Profitability & Quality MGTX
Gross Margin N/A 97.9%
Operating Margin 0.0% 46.3%
Net Profit Margin 0.0% 19.9%
Return on Equity (ROE) -100.5% 72.2%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$146M -$28M
Cash Flow Margin N/A -7.0%
Net Cash / Leverage $48M Net Debt (0.44x D/E) $51M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 637.1% (89th %ile) 52.9% (3rd %ile)
Put/Call OI Skew 1.57x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity N/A 51.6% of Rev ($205M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (0) vs MGTX (10)
Institutional Metric CAPR MGTX Criterion Row Edge
Market Capitalization
Scale
$595.4M $844.2M Larger Scale MGTX
Trailing P/E Ratio
Valuation
78.7x 10.1x Lower Multiple MGTX
Forward P/E Ratio
Valuation
78.7x 64.1x Lower Multiple MGTX
Revenue Growth (YoY)
Growth
-7.9% +8608.6% Higher Growth MGTX
Operating Margin (TTM)
Profitability
0.0% 46.3% Higher Margin MGTX
Net Profit Margin
Profitability
0.0% 19.9% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
-100.5% 72.2% Higher ROE MGTX
52-Week Range Position
Momentum
15% ($3–$40) 26% ($7–$15) Stronger Trend MGTX
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 1.65β · 68% Vol Lower Realized Risk MGTX
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite MGTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $398M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 97.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) -$28M ($51M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +30.86 pp
CAPR: +26.23% · MGTX: -4.63%
3M Horizon CAPR +55.92 pp
CAPR: +19.63% · MGTX: -36.29%
6M Horizon MGTX +64.73 pp
CAPR: -70.58% · MGTX: -5.85%
1Y Horizon CAPR +39.65 pp
CAPR: +46.79% · MGTX: +7.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAPR Revenue MGTX Revenue CAPR Op. Margin MGTX Op. Margin Margin Leader
FY2018 $0M N/A -917.0% N/A CAPR
FY2019 $0M $10M -769.5% -438.4% MGTX
FY2020 $0M $20M -4412.6% -401.9% MGTX
FY2021 $0M $40M -8549.9% -193.0% MGTX
FY2022 $0M $20M -1163.9% -730.9% MGTX
FY2023 $30M $10M -95.6% -977.8% CAPR
FY2024 $20M $30M -191.1% -493.4% CAPR
FY2025 N/A $80M N/A -130.2% MGTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs MGTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas MGTX carries 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin). Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with MGTX at +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CAPR cumulative revenue shifted -33.3% while MGTX shifted +700.0%. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus 51.6% of Rev ($205M) (0 disclosures) for MGTX.

MGTX screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus MGTX (72.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.